Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 14

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

490

HTML

30789

Figures (1-2)

219

Tables (1-6)

252

Sum=31750

Apr 14, 2011 (publication date) through Dec 23, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Apr 14, 2011; 17(14): 1879-1888
Published online Apr 14, 2011. doi: 10.3748/wjg.v17.i14.1879

Full Size Figure Download Figure

Figure 1 Disposition of patients at each stage of the study. EGFR: Epidermal growth factor receptor; PD: Progressive disease.

Citation: Lim R, Sun Y, Im SA, Hsieh RK, Yau TK, Bonaventura A, Cheirsilpa A, Esser R, Mueser M, Advani S. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study. World J Gastroenterol 2011; 17(14): 1879-1888
URL: https://www.wjgnet.com/1007-9327/full/v17/i14/1879.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i14.1879